Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
APVO

APVO - Aptevo Therapeutics Inc Stock Price, Fair Value and News

0.14USD0.00 (0.00%)Market Closed
Watchlist

Market Summary

USD0.140.00
Market Closed
0.00%

APVO Stock Price

View Fullscreen

APVO RSI Chart

APVO Valuation

Market Cap

2.5M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

0.85

EV/EBITDA

0.28

Price/Free Cashflow

-0.2

APVO Price/Sales (Trailing)

APVO Profitability

EBT Margin

-1725.14%

Return on Equity

-109.74%

Return on Assets

-59.53%

Free Cashflow Yield

-503.42%

APVO Fundamentals

APVO Revenue

Revenue (TTM)

3.1M

APVO Earnings

Earnings (TTM)

-16.2M

Earnings Growth (Yr)

17.14%

Earnings Growth (Qtr)

20.31%

Breaking Down APVO Revenue

Last 7 days

-6.2%

Last 30 days

-6.2%

Last 90 days

-21.0%

Trailing 12 Months

-92.9%

How does APVO drawdown profile look like?

APVO Financial Health

Current Ratio

3.09

Debt/Equity

0.1

Debt/Cashflow

-8.53

APVO Investor Care

Shares Dilution (1Y)

245.99%

Diluted EPS (TTM)

-2.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202213.0M37.7M20.4M3.1M
20216.8M9.4M11.0M12.3M
202025.4M18.4M11.3M4.3M
201926.0M26.6M29.7M32.4M
201816.6M19.9M19.5M23.1M
201723.9M17.3M20.6M14.7M
201630.0M33.1M29.4M29.8M
201500033.6M

Tracking the Latest Insider Buys and Sells of Aptevo Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 29, 2024
taylor daphne
acquired
-
-
792
svp, cfo
Jan 28, 2024
white marvin l
acquired
-
-
4,792
president and ceo
Jan 28, 2024
lamothe jeffrey g.
acquired
-
-
1,833
evp, coo
Aug 09, 2023
grant grady iii
acquired
-
-
3,571
-
Aug 09, 2023
niederhuber john
acquired
-
-
3,571
-
Aug 09, 2023
harsanyi zsolt
acquired
-
-
3,571
-
Aug 09, 2023
kunz barbara lopez
acquired
-
-
3,571
-
Aug 09, 2023
abdun-nabi daniel
acquired
-
-
3,571
-
Aug 08, 2023
lamothe jeffrey g.
acquired
-
-
13,812
evp, coo
Aug 08, 2023
kwon soyoung
acquired
-
-
9,375
svp, gc, bd & corp affairs

1–10 of 50

Which funds bought or sold APVO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
sold off
-100
-16,000
-
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
new
-
2,036
2,036
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
47,444
47,444
-%
Feb 14, 2024
CANTOR FITZGERALD, L. P.
added
3.86
-8,003
10,594
-%
Feb 14, 2024
VANGUARD GROUP INC
reduced
-58.51
-56,349
16,602
-%
Feb 14, 2024
EARNEST PARTNERS LLC
sold off
-100
-5.00
-
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
18,934
18,934
-%
Feb 14, 2024
SABBY MANAGEMENT, LLC
reduced
-73.81
-377,022,000
63,254,000
0.06%
Feb 14, 2024
Squarepoint Ops LLC
new
-
25,104
25,104
-%

1–10 of 34

Are Funds Buying or Selling APVO?

Are funds buying APVO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APVO
No. of Funds

Unveiling Aptevo Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.99%
1,731,034
SC 13G
Feb 14, 2023
rtw investments, lp
0%
0
SC 13G/A
Nov 26, 2021
tang capital partners lp
0.0%
0
SC 13D/A
Nov 22, 2021
tang capital partners lp
18.8%
921,336
SC 13D/A
Jun 21, 2021
tang capital partners lp
39.6%
1,760,000
SC 13D/A
Feb 16, 2021
point72 asset management, l.p.
0%
0
SC 13G/A
Feb 16, 2021
armistice capital, llc
0%
0
SC 13G/A
Feb 12, 2021
rtw investments, lp
6.96%
288,236
SC 13G/A
Feb 12, 2021
stonepine capital management, llc
0.4%
18,280
SC 13G/A
Feb 11, 2021
renaissance technologies llc
5.81%
254,423
SC 13G/A

Recent SEC filings of Aptevo Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 06, 2024
8-K
Current Report
Jan 30, 2024
DEFR14A
DEFR14A
Jan 30, 2024
4
Insider Trading
Jan 30, 2024
4
Insider Trading
Jan 30, 2024
4
Insider Trading
Jan 16, 2024
DEFR14A
DEFR14A
Dec 22, 2023
DEF 14A
DEF 14A
Dec 12, 2023
PRE 14A
PRE 14A
Nov 30, 2023
EFFECT
EFFECT

Peers (Alternatives to Aptevo Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aptevo Therapeutics Inc News

Latest updates
Yahoo Finance3 months ago
InvestorPlace11 months ago

Aptevo Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q4
Revenue---27,861,0003,114,0003,665,0003,096,0003,110,0002,421,0002,373,0001,463,0003,985,6676,508,3339,031,0009,011,0007,360,0007,022,0006,346,0005,824,0006,826,0004,071,0002,818,000
Operating Expenses-----------7,280,0007,622,000--10,404,00011,162,000-----
  S&GA Expenses-9.0%3,010,0003,307,0003,697,0003,859,0003,162,0003,479,0004,110,0003,947,0004,280,0003,215,0002,840,0003,616,0003,528,5003,863,0004,279,0004,528,0006,577,5006,940,0007,023,0007,592,0008,556,500
  R&D Expenses4.4%4,674,0004,477,0003,865,0004,866,0004,543,0004,367,0004,722,0005,362,0004,912,0004,494,0004,440,0004,006,0004,408,0007,596,0006,125,0006,634,0008,899,0008,574,0009,713,0008,199,0009,186,000
EBITDA Margin-557.1%-16.96-2.58-1.40-4.05-4.28-4.77-5.60-7.67-12.14-4.60-----------
Income Taxes---------------999,000-------7,714,000
Earnings Before Taxes-----------6,948,000----12,084,000---14,096,000-12,562,000-13,155,000-13,908,000-17,409,000
EBT Margin-555.9%-17.25-2.63-1.42-4.14-4.37-4.88-5.74-7.86-12.47-4.74-----------
Net Income39.3%-4,642,000-7,644,00028,010,000-7,697,000-6,272,000-6,997,000-7,932,000-7,256,000-7,053,000-6,791,000-6,803,0002,897,000-8,174,000-6,924,000-13,332,000-12,018,000-14,128,500-12,562,000-13,144,000-13,854,000-9,760,000
Net Income Margin723.0%2.580.310.19-2.23-2.32-2.66-3.10-4.08-4.12-1.66-----------
Free Cashflow13.9%-5,939,000-6,900,000-3,188,000-5,235,000-3,998,000-5,255,000-5,444,000-7,695,000-6,123,000-7,387,000-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-6.2%27.0029.0035.0034.0032.0039.0045.0057.0064.0071.0069.0054.0037.0019.0025.0053.0061.0066.0081.0067.0079.00
  Current Assets-6.9%21.0023.0028.0027.0025.0031.0042.0053.0059.0066.0063.0047.0031.0010.0015.0030.0037.0044.0058.0049.0060.00
    Cash Equivalents-9.0%19.0021.0025.0023.0022.0029.0035.0045.0052.0060.0058.0040.0025.008.0012.0012.0018.0021.0037.0031.0028.00
  Inventory----------------6.007.007.004.002.004.00
  Net PPE-10.8%1.001.001.001.002.002.002.002.003.003.003.003.003.003.004.004.004.005.005.005.006.00
Liabilities-2.0%12.0013.0012.0016.0016.0016.0051.0055.0057.0058.0058.0037.0035.0010.0010.0042.0041.0040.0042.0037.0035.00
  Current Liabilities-1.1%7.007.006.009.008.007.0024.0035.0032.0031.0029.0015.007.007.007.0038.0037.0017.0018.0018.0015.00
  Long Term Debt----1.002.00--4.00---------20.0019.0019.0019.00
    LT Debt, Current----2.002.002.002.0012.0011.0011.0010.005.00---20.00-----
    LT Debt, Non Current----1.002.00--4.00---------20.0019.0019.0019.00
Shareholder's Equity-9.4%15.0016.0023.0018.0016.0023.002161.007.0014.0011.0017.002.009.0015.0012.0020.0026.0039.0030.0044.00
  Retained Earnings-3.0%-217-211-203-206-201-193-221-214-207-200-192-185-178-171-164-167-159-152-139-127-113
  Additional Paid-In Capital2.1%232227226224217217216215215215203202181180180180179179179158157
Shares Outstanding91.8%14.008.007.006.005.005.005.005.005.005.004.004.003.00--------
Float------18.00---93.00---24.00---37.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-29.9%-6,240-4,8034,566-5,939-6,896-3,070-5,117-3,880-5,242-5,053-7,504-6,123-7,387-4,633-11,175-5,100-7,548-15,891-13,844-7,292-11,146
  Share Based Compensation-2.2%455465915357359485601178319572574198343301413269334401594493481
Cashflow From Investing------4.00---118-13.00-391-191-88.00--28,120-4,250--1539,04127,949
Cashflow From Financing803.1%4,344481-1,8735,998-500-3,178-4,936-3,076-3,0218,31623,94221,24824,730--22,104-13524.00-11320,37339.00-583

APVO Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Royalty revenue   $ 3,114
Revenue from Contract with Customer, Product and Service [Extensible List]   us-gaap:RoyaltyMember
Operating expenses:    
Research and development$ (3,887)$ (4,477)$ (13,516)$ (13,208)
General and administrative(2,674)(3,307)(8,978)(10,863)
Loss from operations(6,561)(7,784)(22,494)(20,957)
Other income (expense):    
Other income (expense) from continuing operations, net227(25)390(4,048)
Gain related to sale of non-financial asset  9,650 
Gain on extinguishment of liability related to sale of royalties   37,182
Net (loss) income from continuing operations(6,334)(7,809)(12,454)12,177
Discontinued operations:    
Income from discontinued operations 165946492
Net (loss) income$ (6,334)$ (7,644)$ (11,508)$ 12,669
Basic and diluted net (loss) income per share from continuing operations:    
Basic$ (0.5)$ (1.53)$ (1.38)$ 2.43
Diluted(0.5)(1.53)(1.38)2.43
Basic net (loss) income per share(0.5)(1.5)(1.28)2.52
Diluted net (loss) income per share$ (0.5)$ (1.5)$ (1.28)$ 2.52
Shares used in calculation:    
Basic shares used in calculation12,579,0125,090,5929,006,5425,017,864
Diluted shares used in calculation12,579,0125,090,5929,006,5425,019,552

APVO Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 19,110$ 22,635
Royalty and milestone receivable 2,500
Prepaid expenses1,3671,571
Other current assets649744
Total current assets21,12627,450
Property and equipment, net1,0111,462
Operating lease right-of-use asset4,9925,303
Total assets27,12934,215
Current liabilities:  
Accounts payable and other accrued liabilities4,0003,499
Accrued compensation1,5252,105
Current portion of long-term debt 2,000
Other current liabilities1,3111,102
Total current liabilities6,8368,706
Long-term debt 1,456
Operating lease liability5,5756,079
Total liabilities12,41116,241
Stockholders' equity:  
Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding
Common stock: $0.001 par value; 500,000,000 shares authorized; 14,465,703 and 6,466,294 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively5648
Additional paid-in capital232,207223,962
Accumulated deficit(217,545)(206,036)
Total stockholders' equity14,71817,974
Total liabilities and stockholders' equity$ 27,129$ 34,215
APVO
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEwww.aptevotherapeutics.com
 EMPLOYEES45

Aptevo Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aptevo Therapeutics Inc? What does APVO stand for in stocks?

APVO is the stock ticker symbol of Aptevo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptevo Therapeutics Inc (APVO)?

As of Thu Feb 22 2024, market cap of Aptevo Therapeutics Inc is 2.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APVO stock?

You can check APVO's fair value in chart for subscribers.

What is the fair value of APVO stock?

You can check APVO's fair value in chart for subscribers. The fair value of Aptevo Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aptevo Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APVO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aptevo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APVO is over valued or under valued. Whether Aptevo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aptevo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APVO.

What is Aptevo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, APVO's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 0.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APVO PE ratio will change depending on the future growth rate expectations of investors.